Novartis | Cafepharma Message Boards | Pharma Sales, Device Sales, Lab ... Biopharma news today spans M&A, clinical wins and regulatory milestones, as companies push forward in gene therapy, obesity and chronic disease treatments. Novartis pens $2B deal for allergy biotech with potential Xolair successorNovartis boardEisai, Alzheon drill down on promising results in high-risk Alzheimer’s subsetEisai board March 27 2026 - Novartis pens $2B deal for allergy biotech with ...
Amid an outpouring of pharma investment dollars into China, Novartis is the latest multinational drugmaker lining up to bolster its research and production operations in the country. The Swiss pharma will collectively invest more than 3.3 billion Chinese yuan (roughly $480 million) to soup up... Novartis joins Lilly, AZ in China expansion with $480M commitment to ... Novartis has penned a $2 billion deal for a biotech whose next-gen anti-immunoglobulin E (IgE) program could offer a worthy successor to Xolair.
novartis nfl partnership, Excellergy has been snapped up by the Swiss pharma only five months after emerging with $70 million in funds. 🎧 CP Midday Brief: Novartis Spends Billions As Novo Defends Wegovy Friday, - 12:26 pm Novartis has jettisoned an anti-cancer protein from its pipeline after the molecule failed to shrink tumors in 30 patients with advanced disease. The pharma giant halted the phase 1 trial of QEQ278 and has dropped the candidate entirely, a spokesperson confirmed with Fierce Biotech.
